Don’t be late! Timely identification of cognitive impairment in people with multiple sclerosis: a study protocol

Autor: Pauline T. Waskowiak, Brigit A. de Jong, Bernard M. J. Uitdehaag, Shalina R. D. Saddal, Jip Aarts, Aïda A. M. Roovers, Pim van Oirschot, Vincent de Groot, Frederieke G. Schaafsma, Karin van der Hiele, Marit F. L. Ruitenberg, Menno M. Schoonheim, Guy A. M. Widdershoven, Sabina van der Veen, Esther C. F. Schippers, Martin Klein, Hanneke E. Hulst, Don’t be late! Consortium

Publikováno v: BMC Neurology, Vol 24, Iss 1, Pp 1-10 (2024)

Abstract Background Cognitive impairment occurs in up to 65% of people with multiple sclerosis (PwMS), negatively affecting daily functioning and health-related quality of life. In general, neuropsychological testing is not part of standard MS-care d

Externí odkaz: https://doaj.org/article/c91246a38f82435a9be1590372a637ce

The role of diet in multiple sclerosis onset and course: results from a nationwide retrospective birth‐year cohort

Autor: Floor C. Loonstra, Lodewijk R. J. deRuiter, Menno M. Schoonheim, Bastiaan Moraal, Eva M. M. Strijbis, Brigit A. deJong, Bernard M. J. Uitdehaag

Publikováno v: Annals of Clinical and Translational Neurology, Vol 10, Iss 8, Pp 1268-1283 (2023)

Abstract Objective To examine (1) the association between childhood diet and developing MS, age of onset and onset type and (2) the association between diet at age 50 and disability and MRI volumes in people with MS (PwMS). Methods The study enrolled

Externí odkaz: https://doaj.org/article/f6db01a4a2124fe4aa358695259ddd35

Exploring Vitreous Haze as a Potential Biomarker for Accelerated Glymphatic Outflow and Neurodegeneration in Multiple Sclerosis: A Cross-Sectional Study

Autor: Sezgi Kaçar, Danko Coric, Giovanni Ometto, Giovanni Montesano, Alastair K. Denniston, Pearse A. Keane, Bernard M. J. Uitdehaag, David P. Crabb, Menno M. Schoonheim, Axel Petzold, Eva M. M. Strijbis

Publikováno v: Brain Sciences, Vol 14, Iss 1, p 36 (2023)

Background: The glymphatic system removes neurodegenerative debris. The ocular glymphatic outflow is from the eye to the proximal optic nerve. In multiple sclerosis (MS), atrophy of the optic nerve increases the glymphatic outflow space. Here, we tes

Externí odkaz: https://doaj.org/article/709d0031c41c410a95b2c622875e7d3c

Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis

Autor: Alyssa A Toorop, Zoé L E van Kempen, Maurice Steenhuis, Jessica Nielsen, L G F Sinnige, Gert van Dijk, Christiaan M Roosendaal, Edo P J Arnoldus, Elske Hoitsma, Birgit I Lissenberg-Witte, Brigit A de Jong, Bob W van Oosten, Eva M M Strijbis, Bernard M J Uitdehaag, Theo Rispens, Joep Killestein

Publikováno v: Journal of Neurology, Neurosurgery and Psychiatry, 94(6), 482-486. BMJ Publishing Group
Toorop, A A, van Kempen, Z L E, Steenhuis, M, Nielsen, J, Sinnige, L G F, van Dijk, G, Roosendaal, C M, Arnoldus, E P J, Hoitsma, E, Lissenberg-Witte, B I, de Jong, B A, Oosten, B W V, Strijbis, E M M, Uitdehaag, B M J, Rispens, T & Killestein, J 2023, ' Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 94, no. 6, pp. 482-486 . https://doi.org/10.1136/jnnp-2022-330467

BackgroundNatalizumab is effective in the treatment of multiple sclerosis (MS). In 2021, the European Medicines Agency approved the subcutaneous (SC) variant of natalizumab which can be used instead of intravenous administration. However, the course

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7605d557613158f19e33be9532286f
http://www.scopus.com/inward/record.url?scp=85151850870&partnerID=8YFLogxK

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial

Autor: Marco Battaglini, Hugo Vrenken, Riccardo Tappa Brocci, Giordano Gentile, Ludovico Luchetti, Adriaan Versteeg, Mark S. Freedman, Bernard M. J. Uitdehaag, Ludwig Kappos, Giancarlo Comi, Andrea Seitzinger, Dominic Jack, Maria Pia Sormani, Frederik Barkhof, Nicola De Stefano

Publikováno v: European Journal of Neurology, 29(7), 2024-2035. Wiley-Blackwell
Battaglini, M, Vrenken, H, Tappa Brocci, R, Gentile, G, Luchetti, L, Versteeg, A, Freedman, M S, Uitdehaag, B M J, Kappos, L, Comi, G, Seitzinger, A, Jack, D, Sormani, M P, Barkhof, F & de Stefano, N 2022, ' Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial : Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a ', European Journal of Neurology, vol. 29, no. 7, pp. 2024-2035 . https://doi.org/10.1111/ene.15314
European Journal of Neurology, 29(7), 2024-2035. Wiley-Blackwell Publishing Ltd

Background and purpose: In the REFLEX trial (ClinicalTrials.gov identifier: NCT00404352), patients with a first clinical demyelinating event (FCDE) displayed significantly delayed onset of multiple sclerosis (MS; McDonald criteria) when treated with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51727e30acc81c73735b4c3d97b6b2ca
http://www.scopus.com/inward/record.url?scp=85127440878&partnerID=8YFLogxK